Alumis jumps after skin disease drug meets main goal in late-stage trials

Alumis

06/01/2026 12:15

** Shares of biopharma firm Alumis ALMS.O jump 17.2% to $9.74 premarket

** ALMS says its experimental pill, envudeucitinib, met the main goal in two late-stage studies in patients with moderate-to-severe plaque psoriasis

** In both the trials, envudeucitinib showed clearer skin compared to placebo after 24 weeks of treatment

** Plaque psoriasis is an immune‑mediated skin disease where the immune system becomes overactive and causes skin cells to grow too quickly

** Alumis plans to submit a marketing application to the U.S. FDA in H2 2026

** In the last 12 months, stock down 14.9% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))